News
KNTE
2.650
0.00%
0.000
*News On Kinnate Biopharma Inc. (KNTE) Now Under XOMA
Dow Jones · 04/03 21:08
Kinnate Biopharma’s Strategic Shift and Corporate Evolution
TipRanks · 04/03 13:42
XOMA CORPORATION ANNOUNCES CLOSING OF TENDER OFFER
Reuters · 04/03 13:00
Weekly Report: what happened at KNTE last week (0325-0329)?
Weekly Report · 04/01 09:08
Kinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 36 cents per share. Wall Street expected the company to report a loss of 42 cents. The average analyst rating on the company's shares is "buy"
Reuters · 03/29 19:05
Weekly Report: what happened at KNTE last week (0318-0322)?
Weekly Report · 03/25 09:08
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
XOMA Corporation has entered into a merger agreement to acquire Kinnate Biopharma Inc. The acquisition is expected to close in April 2024. XOMA has extended the Offer's expiration date to April 2, 2024. Kinnate stockholders will receive an additional cash amount of up to $0.2527 per share.
Benzinga · 03/19 20:15
*XOMA: Cash Amount That Kinnate Stockholders Will Receive in Offer Is $2.5879 Per Shr >XOMA
Dow Jones · 03/19 20:13
*XOMA to Pay Base Cash Price of $2.3352 Per Shr of Kinnate and Additional Cash Amount of Not More Than $0.2527 Per Shr, Plus One Non-Tradeable CVR
Dow Jones · 03/19 20:12
*XOMA to Acquire Kinnate Biopharma >XOMA KNTE
Dow Jones · 03/19 20:11
Weekly Report: what happened at KNTE last week (0311-0315)?
Weekly Report · 03/18 09:08
Kinnate Biopharma Inc <KNTE.OQ> expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 18. The average analyst rating on the shares is "buy" and the median 12-month price target is $2.50.
Reuters · 03/15 21:25
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Kinnate Biopharma Inc. To XOMA Corporation. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 03/13 10:49
Weekly Report: what happened at KNTE last week (0304-0308)?
Weekly Report · 03/11 09:08
Weekly Report: what happened at KNTE last week (0226-0301)?
Weekly Report · 03/04 09:08
BUZZ-U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
S&P 500 and Nasdaq climb on Friday as chipmakers extend gains. Dow Jones Industrial Average up 0.17% at 39,060.77. Copper miners, NetApp and Madrigal Pharma are among the day's losers. Treasury yields dip on soft economic data and remarks from Fed officials.
Reuters · 03/01 19:20
BUZZ-U.S. STOCKS ON THE MOVE-Cooper, US energy stocks, Vista Outdoor
U.S. Stocks struggled for direction on Friday. Dow Jones Industrial Average was down 0.01% at 38,992.07. The top three S&P 500 percentage gainers were NetApp, Dell and The Cooper Companies. The Nasdaq Composite was up 0.33%.
Reuters · 03/01 15:52
BUZZ-Kinnate Bio rises after selling a cancer therapy to Pierre Fabre
Kinnate Biopharma sells cancer therapy to Pierre Fabre for up to $31 million. Shares of drug developer rise 5.1% to $2.60. Stock down 50.8% in the last 12 months. Company sells experimental cancer therapy called exarafenib to France-based company.
Reuters · 03/01 14:40
Kinnate Biopharma Strikes Major Deal on Drug Rights
TipRanks · 03/01 14:03
Kinnate Biopharma Sells Exarafenib Assets to Pierre Fabre Labs
Kinnate Biopharma is selling its pan-RAF inhibitor, exarafenib, to Pierre Fabre Medicament, a global oncology company. The company says the sale is part of its exploration of strategic alternatives. Kinnate will receive a total consideration of up to $31 million.
Dow Jones · 03/01 13:54
More
Webull provides a variety of real-time KNTE stock news. You can receive the latest news about Kinnate Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KNTE
Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).